JACC Specialty Journals

Latest Episodes:

XGBoost Model with CMR Features for Prognostic Assessment in Patients With ST‑Segment Elevation Myocardial Infarction | JACC: Asia Oct 20, 2026

Show notes

Commentary by Dr. Yoriyasu Suzuki.

Design and Rationale of GPS-CAD: Global Pretest Probability Study of Coronary Artery Disease | JACC: Asia Oct 20, 2026

Show notes

Commentary by Dr. Junjie Yang.

Prediction of Paroxysmal Atrial Fibrillation with Incorporating Genomic Information Into AI-Based ECG Analysis | JACC: Asia Oct 20, 2026

Show notes

Commentary by Dr. Qinkai Yu.

October 2026 Summary | JACC: CardioOncology Oct 20, 2026

Show notes

Editor-in-Chief Dr. Bonnie Ky introduces the October 2026 issue of JACC: CardioOncology, featuring Part 1 of a special focus on immunology and cardio-oncology. This issue brings together state-of-the-art reviews, primers, original research, and clinical cases examining the immune system's central role in cancer and cardiovascular disease. Topics include the mechanisms and clinical implications of cancer immunotherapies and the immune system's contributions to the cardiovascular effects of cytotoxic chemotherapy, with implications for scientific discovery and patient care.

Fibrotic Rewiring of CD8+ T-cells by Doxorubicin Drives Pathological Remodeling of Cardiac Extracellular Matrix | JACC: CardioOncology Oct 20, 2026

Show notes

Dr. Caitlin O'Meara discusses a JACC: CardioOncology study showing that doxorubicin reprograms CD8+ T cells into matrix-remodeling T cells (mxT-cells) that produce lysyl oxidase (LOX) and stiffen the cardiac extracellular matrix through HIF1α-P53-TGFβ signaling. She explains how this new immune mechanism of anthracycline cardiotoxicity could lead to therapies that prevent cardiac fibrosis, cardiomyopathy, and heart failure in patients treated with chemotherapy.

High-Sensitivity Cardiac Troponin T and I Discordance in Patients Receiving Immune Checkpoint Inhibitors | JACC: CardioOncology Oct 20, 2026

Show notes

Dr. David Austin discusses a JACC: CardioOncology study showing that high-sensitivity cardiac troponin T was elevated in 37.9% of patients starting immune checkpoint inhibitor (ICI) therapy, compared with only 1.8% for high-sensitivity troponin I, a discordance linked to older age, male sex, and kidney dysfunction. He explains what this means for troponin assay selection, baseline testing, and ICI myocarditis surveillance, helping cardiologists and oncologists avoid unnecessary cancer treatment interruptions and immunosuppression.

Inflammatory Cell Profiles in Early- and Late-Manifestation Immune Checkpoint Inhibitor Myocarditis | JACC: CardioOncology Oct 20, 2026

Show notes

Dr. Cristina Gil-Cruz discusses a JACC: CardioOncology study comparing early- and late-manifestation immune checkpoint inhibitor (ICI) myocarditis, where endomyocardial biopsies showed greater T-cell and macrophage infiltration in early cases despite similar left ventricular ejection fraction and fibrosis. She explains what these inflammatory cell profiles mean for cardio-oncology care, from immunosuppression and ICI rechallenge to balancing cardiac safety with effective cancer immunotherapy.

Impact of Device Position and Aortic Valve Prolapse on Outcomes After Transcatheter VSD Closure | JACC: Asia Oct 07, 2026

Show notes

Commentary by Dr. Timothy Un.

Prognostic Impact of Residual Thrombus After Aspiration Thrombectomy in ST-Elevation Myocardial Infarction | JACC: Asia Oct 07, 2026

Show notes

Commentary by Dr. Ziyad Ghazzal.

Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials | JACC: Asia Oct 07, 2026

Show notes

Commentary by Dr. Yihang Fan.